This non-invasive test uses a blood sample to detect EGFR mutations in circulating tumor DNA. It is especially helpful when a tissue biopsy is not feasible or when ongoing monitoring is required to assess treatment response or the emergence of resistance mutations.
Patients with advanced non-small cell lung cancer who are unable to provide a tissue sample or require regular monitoring during or after EGFR-targeted therapy.
